他汀类药物在 COVID-19 中的潜在作用。
Potential role of statins in COVID-19.
机构信息
Department of Respiratory and Critical Care Medicine, Singapore General Hospital.
Department of Respiratory and Critical Care Medicine, Singapore General Hospital.
出版信息
Int J Infect Dis. 2020 Jul;96:615-617. doi: 10.1016/j.ijid.2020.05.115. Epub 2020 Jun 2.
Abstract
Patients with COVID-19 infection have an increased risk of cardiovascular complications and thrombotic events. Statins are known for their pleiotropic anti-inflammatory, antithrombotic and immunomodulatory effects. They may have a potential role as adjunctive therapy to mitigate endothelial dysfunction and dysregulated inflammation in patients with COVID-19 infection.
摘要
感染 COVID-19 的患者心血管并发症和血栓事件的风险增加。他汀类药物具有多效性抗炎、抗血栓和免疫调节作用。它们可能作为辅助治疗，减轻 COVID-19 感染患者的内皮功能障碍和失调的炎症。
相似文献
1
Potential role of statins in COVID-19.他汀类药物在 COVID-19 中的潜在作用。
Int J Infect Dis. 2020 Jul;96:615-617. doi: 10.1016/j.ijid.2020.05.115. Epub 2020 Jun 2.
2
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia.预防家族性高胆固醇血症的新冠肺炎患者出现内皮功能障碍和血栓形成事件。
J Clin Lipidol. 2020 Sep-Oct;14(5):617-618. doi: 10.1016/j.jacl.2020.06.006. Epub 2020 Jun 15.
3
Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.西他列汀在新型冠状病毒肺炎中的重新定位：对肺部血管紧张素转换酶2、二肽基肽酶4和炎症细胞因子风暴的影响
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):10-12. doi: 10.18502/ijaai.v19i(s1.r1).2849.
4
Meta-analysis of Effect of Statins in Patients with COVID-19.他汀类药物对新型冠状病毒肺炎患者影响的荟萃分析
Am J Cardiol. 2020 Nov 1;134:153-155. doi: 10.1016/j.amjcard.2020.08.004. Epub 2020 Aug 12.
5
Are statins safe in patients with COVID-19?他汀类药物对新冠肺炎患者安全吗？
J Clin Lipidol. 2020 Jul-Aug;14(4):396-397. doi: 10.1016/j.jacl.2020.06.009. Epub 2020 Jun 22.
6
Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.卡维地洛与2019冠状病毒病：在降低严重急性呼吸综合征冠状病毒2传染性和感染严重程度方面的潜在作用
Am J Med Sci. 2020 Sep;360(3):300. doi: 10.1016/j.amjms.2020.05.030. Epub 2020 May 28.
7
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.住院期间使用他汀类药物与 COVID-19 患者的死亡率降低相关。
Cell Metab. 2020 Aug 4;32(2):176-187.e4. doi: 10.1016/j.cmet.2020.06.015. Epub 2020 Jun 24.
8
Statins in coronavirus outbreak: It's time for experimental and clinical studies.冠状病毒爆发中的他汀类药物：是时候进行实验和临床研究了。
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
9
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
10
Tocilizumab in COVID-19: Beware the risk of intestinal perforation.托珠单抗治疗新型冠状病毒肺炎：谨防肠穿孔风险。
Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.
引用本文的文献
1
Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.弥合心血管疾病与新冠病毒疾病之间的差距：氧化型低密度脂蛋白假说。
Front Med (Lausanne). 2025 Aug 6;12:1588062. doi: 10.3389/fmed.2025.1588062. eCollection 2025.
2
The mechanistic basis linking cytokine storm to thrombosis in COVID-19.将细胞因子风暴与COVID-19中的血栓形成联系起来的机制基础。
Thromb Update. 2022 Aug;8:100110. doi: 10.1016/j.tru.2022.100110. Epub 2022 May 18.
3
Uncovering the Effect of SARS-CoV-2 on Liver Metabolism via Genome-Scale Metabolic Modeling for Reprogramming and Therapeutic Strategies.通过基因组规模代谢模型揭示SARS-CoV-2对肝脏代谢的影响，用于重新编程和治疗策略。
ACS Omega. 2024 Mar 22;9(13):15535-15546. doi: 10.1021/acsomega.4c00392. eCollection 2024 Apr 2.
4
Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial.阿托伐他汀降低重症和危重症 COVID-19 患者 28 天死亡率：一项随机对照试验。
Respir Res. 2024 Feb 22;25(1):97. doi: 10.1186/s12931-024-02732-2.
5
Statin use and clinical outcomes in hospitalized COVID-19 patients: A retrospective analysis in Riyadh, Saudi Arabia.住院 COVID-19 患者中他汀类药物的使用与临床结局：沙特阿拉伯利雅得的回顾性分析。
Saudi Med J. 2024 Feb;45(2):171-178. doi: 10.15537/smj.2024.45.2.20230589.
6
Different effects of vaccine on VST in critical and non-critical COVID-19 patients: A retrospective study of 363 cases.疫苗对重症和非重症COVID-19患者疫苗特异性T细胞的不同影响：一项363例病例的回顾性研究
Heliyon. 2023 May;9(5):e16017. doi: 10.1016/j.heliyon.2023.e16017. Epub 2023 May 1.
7
Severe COVID-19: Drugs and Clinical Trials.重症新型冠状病毒肺炎：药物与临床试验
J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893.
8
The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study.他汀类药物对合并糖尿病的 COVID-19 患者呼吸系统症状和肺纤维化的影响：一项纵向多中心研究。
Arch Immunol Ther Exp (Warsz). 2023 Feb 28;71(1):8. doi: 10.1007/s00005-023-00672-1.
9
Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner.他汀类药物使用与 COVID-19 住院患者结局的关联：使用超级学习者的电子健康记录分析。
BMC Infect Dis. 2023 Feb 24;23(1):115. doi: 10.1186/s12879-023-08026-0.
10
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years.用于预防和治疗新型冠状病毒肺炎及其并发症的药物：过去两年我们所了解情况的最新进展
Front Pharmacol. 2022 Oct 10;13:987816. doi: 10.3389/fphar.2022.987816. eCollection 2022.
本文引用的文献
1
COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.由弥漫性肺血栓和对溶栓有反应的肺内皮功能障碍驱动的COVID-19危重病病理生理学。
Clin Transl Med. 2020 Jun;10(2):e44. doi: 10.1002/ctm2.44. Epub 2020 Jun 5.
2
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.美国心力衰竭学会/美国心脏病学会/美国心脏协会联合声明回应关于在2019冠状病毒病中使用肾素-血管紧张素-醛固酮系统拮抗剂的担忧。
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
3
Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily.重症新型冠状病毒肺炎感染与血栓性微血管病：成功来之不易。
Br J Haematol. 2020 Jun;189(6):e227-e230. doi: 10.1111/bjh.16783. Epub 2020 May 23.
4
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
5
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
6
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
7
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers.SARS-CoV-2 的临床表型：对临床医生和研究人员的启示。
Eur Respir J. 2020 May 21;55(5). doi: 10.1183/13993003.01028-2020. Print 2020 May.
8
COVID19 coagulopathy in Caucasian patients.COVID19 凝血障碍与高加索人群。
Br J Haematol. 2020 Jun;189(6):1044-1049. doi: 10.1111/bjh.16749. Epub 2020 May 17.
9
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
10
Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.重症新型冠状病毒肺炎中肺血栓形成现象的病理学证据
J Thromb Haemost. 2020 Jun;18(6):1517-1519. doi: 10.1111/jth.14844.
Zotero 插件